

May 29, 2008

Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP)

Section 15 of O.Reg. 201/96 made under the *Ontario Drug Benefit Act* (ODBA) allows the Executive Officer (EO) to enter into agreements with manufacturers to establish Drug Benefit Prices (DBPs) for products reimbursed under the Exceptional Access Program (EAP). The EAP was formerly referred to as the Individual Clinical Review (ICR) program or 'Section 8'.

Please be advised that the ministry has entered into agreements with the manufacturers of Nexavar (Bayer Inc.) and Sutent (Pfizer Canada Inc.) and DBPs have been established, as set out below. Effective May 30, 2008 the ministry's Health Network System (HNS) will be updated to ensure that claims for these products are adjudicated according to the agreed DBPs.

DIN	Trade Name	Strength	Dosage Form	DBP
02284227	Nexavar	200mg	Tablet	43.7500
02280795	Sutent	12.5mg	Capsule	62.0357
02280809	Sutent	25mg	Capsule	124.0711
02280817	Sutent	50mg	Capsule	248.1425

Until further notice, for all other products reimbursed under the EAP, pharmacists will continue to be reimbursed their acquisition cost plus the applicable markup (currently 8%).

Helen Stevenson

Executive Officer, Ontario Public Drug Programs